

Effects of Dietary Carbohydrate Restriction with High Protein Intake on Protein Metabolism and the Somatotrophic Axis

Matthew P. Harber, Simon Schenk, Ariel L. Barkan, and Jeffrey F. Horowitz

Divisions of Kinesiology (M.P.H., S.S., J.F.H.) and Endocrinology and Metabolism (A.L.B.), University of Michigan and Veterans Affairs Medical Center, Ann Arbor, Michigan 48109

Context: Alterations in dietary macronutrient intake can influence protein turnover.

Objective: The purpose of this study was to assess the influence of a low-carbohydrate/high-protein diet (LC/HP) on skeletal muscle protein synthesis and whole-body proteolysis, without the confounding influence of a negative energy balance.

Design: Nine-day dietary intervention was applied.

Setting: Subjects remained in the General Clinical Research Center throughout the 9-d study.

Participants: Eight young, healthy volunteers participated.

Intervention: Subjects ate a typical Western diet (60% carbohydrate, 30% fat, 10% protein) for 2 d, followed immediately by 7 d of an isocaloric LC/HP (5% carbohydrate, 60% fat, 35% protein).

Main Outcome Measures: Skeletal muscle fractional synthetic rate

and whole-body proteolysis [leucine rate of appearance in plasma (Ra)] were measured after an overnight fast before and after 2 and 7 d of LC/HP. We also measured plasma concentrations of insulin, GH, and IGF-I.

Results: Leucine Ra was increased ($P = 0.03$) after 2 and 7 d of LC/HP, and muscle fractional synthetic rate was approximately 2-fold higher ($P < 0.01$) after 7 d of LC/HP. Fat free mass was not altered by LC/HP. Average 24-h plasma insulin concentration was 50% lower ($P < 0.001$) after 2 and 7 d of LC/HP, whereas GH secretion and total plasma IGF-I concentrations were unchanged with LC/HP. However, plasma free IGF-I decreased by approximately 30% after 7 d of LC/HP ($P = 0.002$), whereas muscle IGF-I mRNA increased about 2-fold ($P = 0.05$).

Conclusions: Increasing dietary protein content during a 7-d carbohydrate restricted diet stimulated muscle protein synthesis and whole-body proteolysis without a measurable change in fat free mass. (*J Clin Endocrinol Metab* 90: 5175–5181, 2005)

MAINTAINING LEAN TISSUE mass is critical for the preservation of functional capacity and normal metabolic function. Alterations in dietary macronutrient intake can greatly affect the balance between tissue protein synthesis and protein degradation (*i.e.* proteolysis) (1), which is the primary determinant for the maintenance of lean tissue. Specifically, dietary carbohydrate restriction has been found to increase nitrogen excretion, which is believed to be indicative of protein loss (2). On the other hand, high protein intake has been found to increase protein synthesis (3), suggesting that the ingestion of a high-protein diet during carbohydrate restriction may compensate for the protein loss associated with low-carbohydrate diets. However, despite the reemerging popularity of low-carbohydrate/high protein diets (LC/HP), little is understood about the effects of marked alterations in these macronutrients on protein metabolism.

First Published Online June 21, 2005

Abbreviations: eIF, Eukaryotic initiation factor; FSR, fractional synthetic rate; IGFBP, IGF binding protein; α -KIC, α -ketoisocaproate; LC/HP, low-carbohydrate/high-protein diet(s); mTOR, mammalian target of rapamycin; m/z, mass-to-charge ratio(s); Ra, rate of appearance; REE, resting energy expenditure.

JCEM is published monthly by The Endocrine Society (<http://www.endo-society.org>), the foremost professional society serving the endocrine community.

Many of the metabolic effects of a low-carbohydrate diet are attributed to the chronic suppression of plasma insulin. Insulin is considered a potent anabolic hormone, primarily through its role in blunting proteolysis (4), but it has also been shown to aid in the stimulation of protein synthesis under certain conditions (5–7). Protein synthesis is responsive to growth factors, such as IGF-I, through distinct signal transduction pathways, including the protein kinase mammalian target of rapamycin (mTOR) signaling pathway (6). The mTOR pathway regulates protein synthesis through activation of downstream signaling intermediates. Phosphorylation (*i.e.* activation) of downstream targets of mTOR [*e.g.* eukaryotic initiation factor (eIF)4G, ribosomal protein S6] is associated with an enhanced rate of protein synthesis (8, 9). However, the effect of carbohydrate restriction combined with a high protein intake on the secretion of insulin, GH, and IGF-I and mTOR signaling is not clearly understood.

The primary purpose of this study was to determine the influence of dietary carbohydrate restriction, in combination with a high protein intake, on skeletal muscle protein synthesis and whole-body protein degradation. We also examined the influence of this diet on GH and insulin secretion, plasma levels of IGF-I, and skeletal muscle IGF-I mRNA to determine whether alterations in these anabolic factors were associated with diet-induced changes in protein metabolism. Finally, we evaluated the effect of the LC/HP on the phos-

phorylation state of key signaling proteins within the mTOR pathway (*i.e.* S6 and eIF4G).

Subjects and Methods

Experimental subjects

Eight healthy subjects (four men and four women) volunteered for participation in this study (age, 29 ± 4 yr; body mass index, 24.2 ± 1.1 kg/m²). Subjects had no evidence of metabolic or cardiovascular disease, were not taking any prescription medications, and were sedentary (*i.e.* <1 h exercise/wk) before their involvement in the study. All women were premenopausal, and studies were performed within the first 2 wk of the follicular phase of their menstrual cycle. All subjects were fully informed of the possible risks associated with the study and signed an informed consent form approved by the University of Michigan Institutional Review Board.

General experimental design

Subjects were admitted to the General Clinical Research Center at the University of Michigan Hospital at 1200 h, 2 d before beginning the week-long experimental LC/HP, and they remained in the hospital until the completion of the 1-wk experimental diet (a total of 9 d). Body composition was assessed using dual-energy x-ray absorptiometry before and at the end of the experimental diet. Postabsorptive resting energy expenditure (REE) was measured during a prestudy screening visit and at 0630 h each morning of the study, using a metabolic cart (Delta-Trac; SensorMedics, Yorba Linda, CA). Oxygen consumption and carbon dioxide production were measured for at least 20 min while subjects were lying supine, awake but undisturbed in a dark, quiet room. Subjects ate a standardized Western diet for the first 2 d of their hospital stay and a LC/HP for the next 7 d (see *Dietary intervention* below for more detail). We assessed whole-body and skeletal muscle protein metabolism using tracer isotope techniques on three separate occasions during their hospital visit: 1) immediately before starting the LC/HP, 2) after 2 d on the diet, and 3) after 1 wk of the diet (see *Measurement of protein kinetics* for more detail). Plasma insulin concentrations were measured hourly throughout the day and every 2 h during the overnight period. Additionally, we measured plasma insulin concentration every 20 min for 2 h after each meal. Plasma GH concentrations were measured at 20-min intervals over a 24-h period starting at 0700 h before introducing the low carbohydrate diet, as well as on the second and seventh days of the diet.

Dietary intervention. After being admitted to the hospital, subjects ate a standardized diet for 2 d, consisting of 60% of total energy from carbohydrate, 30% fat, and 10% protein, and a daily caloric content estimated to maintain body weight [*i.e.* kcal = $1.3 \times$ REE (10)]. This diet approximates the macronutrient content of a normal diet in the United States (11), and using this diet as a control allows us to best evaluate the metabolic consequences of a LC/HP. During the 1-wk LC/HP, subjects consumed a weight-maintaining (*i.e.* kcal = $1.3 \times$ REE) diet consisting of 5% of total energy from carbohydrate, 60% fat, and 35% protein. Daily caloric content for both the standardized control diet and the LC/HP were 40 ± 2 kcal/kg fat free mass (28 ± 1 kcal/kg body weight). On most days, meals were served at 0800, 1300, and 1830 h. However, on days in which protein kinetics were measured, the meals were delayed until 1300, 1645, and 1945 h.

Measurement of protein kinetics. We measured skeletal muscle protein fractional synthetic rate (FSR) before the LC/HP and again after 7 d of the diet. Due to technical limitations, muscle FSR was determined in six subjects. Whole-body proteolysis was also measured immediately before the carbohydrate restricted diet, after 2 d of the diet, and again after 7 d of the diet. At 0600 h in the morning of each of these days, a Teflon catheter was inserted into the antecubital vein of one arm for isotope infusion, and another catheter was placed into a hand vein to obtain arterialized blood samples with use of a heated box (12). Starting at 0650 h, three blood samples were obtained in 5-min intervals from the heated hand vein to determine background [²H₃]-leucine enrichment. A primed constant infusion of [²H₃]-leucine (4.2 μmol/kg priming dose; 0.07 μmol/kg/min continuous infusion) was initiated at 0700 h. On the 2 d that skeletal muscle protein FSR was measured, a muscle biopsy

specimen (~100 mg) was obtained from the vastus lateralis muscle at 0800 h and again at 1300 h for measurement of [²H₃]-leucine incorporation into skeletal muscle. Arterialized blood samples were again obtained in triplicate after 4 h (at 1050, 1055, and 1100 h) and 6 h of the leucine infusion (at 1250, 1255, and 1300 h).

Analytical methods

Leucine rate of appearance (Ra). Whole-body proteolysis was measured as leucine Ra into plasma. Plasma samples (250 μl) were deproteinized with 1.8 ml ice-cold acetone and incubated at -20 C for 15 min, followed by centrifugation for 15 min at 3000 rpm at 5 C. The supernatant was transferred to a new tube and added to 3 ml hexane and 3 ml distilled water, mixed gently for 15 min on a platform shaker and centrifuged for 15 min at 3000 rpm at 5 C. The upper (hexane) layer was then discarded, and the lower (aqueous) layer was dried down overnight under vacuum. Samples were derivatized with *t*-butyldimethylsilyl by adding 100 μl of a 1:1 acetonitrile:*N*-methyl-*N*-tert(*t*-butyldimethylsilyl)tri-fluoroacetamide solution and incubated for 30 min at 70 C. Samples were analyzed via electron ionization using a gas chromatograph-mass spectrometer (Agilent 6890 gas chromatograph with 5973 mass selective detector; Agilent Technologies, Inc., Wilmington, DE), and the abundance at mass-to-charge ratios (*m/z*) of 200 *m/z* (*m*+0) and 203 *m/z* (*m*+3) was measured with selective ion monitoring.

Skeletal muscle FSR. Mixed muscle rate of protein synthesis was determined by evaluating the incorporation of [²H₃]-leucine in muscle samples from the vastus lateralis, according to the methods of Patterson *et al.* (13), using plasma α -ketoisocaproate (α -KIC) enrichment as the precursor pool (14). Briefly, 20–30 mg muscle was minced and homogenized on ice in a 3% trichloroacetic acid solution and centrifuged at 2500 rpm for 15 min. The resulting pellet then underwent four rinses in 2 ml normal saline and was incubated in 1 ml 6 N HCl at 110 C for 24 h. A volume equivalent to 4 mg starting tissue was extracted and derivatized with *t*-butyldimethylsilyl as described above. Samples were analyzed by gas chromatograph-mass spectrometry using electron impact ionization with selective ion monitoring to determine the abundances at 200 (*m*+0), 201, 202, and 203 *m/z*. Muscle enrichment of [²H₃]-leucine was measured as the 203/202 ratio using the standard curve approach from mixtures of known *m*+3/*m*+0 ratios as described previously (13).

Plasma hormone concentrations. Plasma insulin concentration was measured by RIA kit (Linco Research, Inc., St. Charles, MO). Plasma GH was measured in a chemiluminometric assay (Nichols Institute, Inc., San Juan Capistrano, CA) with an assay sensitivity of 10 ng/liter. Total and free IGF-I and IGF binding protein (IGFBP)-3 were measured after acid-ethanol extraction by two-site immunoradiometric assays (Diagnostic Systems Laboratories, Inc., Webster, TX) with a sensitivity of 10 ng/liter.

Skeletal muscle signaling proteins. Western immunoblotting techniques were used to measure total protein content of eIF4G and S6, as well as the content of the phosphorylated form of each protein. Approximately 20 mg tissue was homogenized in ice-cold RIPA buffer and allowed to further dissociate while on ice for 30 min. The homogenate was then centrifuged at $3000 \times g$ for 20 min, and the protein concentration of the supernatant was determined. Samples were then diluted 1:2 with Laemmli sample buffer (containing 5% β -mercaptoethanol) (Bio-Rad Laboratories, Inc., Hercules, CA) and boiled for 5 min before gel electrophoresis. Samples (40 μg protein) were then separated using 4–8% PAGE, and proteins were subsequently transferred to a nitrocellulose membrane and incubated in 5% milk/Tris-buffered saline + tween-20 blocking buffer for 1 h at room temp. After rinsing (3×10 min in Tris-buffered saline + tween-20), blots were incubated in rabbit anti-eIF4G (BL896; Bethyl Laboratories, Inc., Montgomery, TX), rabbit anti-phospho-eIF4G (Ser1108) (no. 2441; Cell Signaling Technology, Inc., Beverly, MA), rabbit anti-S6 ribosomal protein (no. 2212; Cell Signaling Technology, Inc.), or rabbit anti-phospho-S6 ribosomal protein (Ser235/236) (no. 2211; Cell Signaling Technology, Inc.) overnight at 4 C. Blots were then analyzed by incubation with antirabbit IgG coupled to horseradish peroxidase (Cell Signaling Technology, Inc.) and developed using chemiluminescence (Amersham Biosciences, Buckinghamshire, UK). Blots were analyzed using a densitometer (Bio-Rad Laboratories, Inc.).

Skeletal muscle IGF-I mRNA expression. We used real-time RT-PCR to assess the mRNA expression of IGF-I in skeletal muscle samples. Total RNA was isolated from approximately 25 mg frozen muscle by using TRIzol Reagent (Invitrogen, Carlsbad, CA). RNA was DNase-treated (DNA-free; Ambion, Inc., Austin, TX) for purity, and total RNA was determined spectrophotometrically at 260 nm. First-strand cDNA was generated from 2 μ g RNA using Maloney-Murine Leukemia Virus reverse-transcriptase (Invitrogen).

Primer pairs for each gene were designed using DNASTAR (Madison, WI) (Lasergene) computer software. Gene sequences were obtained from GenBank: IGF-I, NM_000618, forward primer 5'-TCATTTTGC-CCTCTGCCTGT-3' and reverse primer 5'-CCTTGGGGGATTTT-GACTGTG-3'; 261-bp product. A BLAST search for each primer was conducted to confirm homologous binding to the target gene.

RT-PCR was performed with use of a DNA engine Opticon continuous fluorescence detection system (MJ Research, Inc., Watertown, MA). Samples for each gene were run simultaneously and in duplicate to control for amplification efficiency. For mRNA quantitation, a real-time PCR mix of 2 \times SYBR Green PCR Master Mix (QIAGEN, Valencia, CA), forward and reverse primers (3 μ mol/liter) and cDNA (12 ng) were run for 36 cycles in a total vol of 25 μ l. After the final cycle, samples were subjected to melting curve analysis to ensure the detection of only one product (15). Additionally, all amplification products were separated by agarose gel electrophoresis to validate the presence and size of the appropriate product. To account for variations in RNA input amounts and transcription efficiency, 18S mRNA was determined, and results were normalized to these values. mRNA levels were quantified for each gene via determination of the critical threshold value as described by Schmittgen *et al.* (16). Finally, the IGF-I mRNA expression for each sample was calculated relative to the IGF-I mRNA expression measured in a control muscle sample. This control muscle sample was taken from another healthy subject who did not undergo the dietary intervention, and the mRNA expression in this sample was measured concurrently with the muscle samples from the subjects in this study.

Calculations

Leucine Ra. Because tracer:tracee ratios were achieved during steady-state conditions, leucine Ra was calculated using the steady-state Steele equation (17). The average tracer:tracee ratio for each set of three samples taken in 5-min intervals before and during the leucine infusion (*e.g.* 1050, 1055, and 1100 h) was used to calculate Ra.

Skeletal muscle protein FSR. FSR was calculated as the rate of [2 H $_3$]-leucine tracer incorporated into muscle protein using the plasma α -KIC enrichment as the precursor pool (14) and the following equation: FSR (% \cdot h $^{-1}$) = [(E $_2$ - E $_1$) \times 100]/[E $_p$ \times (t $_1$ - t $_0$)], where E $_2$ and E $_1$ represent muscle [2 H $_3$]-leucine enrichments after 6 h and 1 h, respectively, E $_p$ represents the average plasma [2 H $_3$]- α -KIC enrichment, and (t $_1$ -t $_0$) represents the time between muscle biopsies (*i.e.* 5 h).

Phosphorylation of S6 and eIF4G. To obtain a more accurate representation of the change in phosphorylation of these proteins with our dietary treatment, we normalized the expression of phosphorylated S6 and eIF4G relative to the total amount of S6 and eIF4G, respectively. Therefore, the phosphorylation state of S6 and eIF4G was calculated by dividing measured amount of phosphorylated S6 and eIF4G by the total amount of each protein.

Statistical analysis

Plasma GH concentration profiles were analyzed by Cluster (version 7), with *t* statistics of 2 and 2 \times 1 configurations for GH increase and decrease, respectively. Baseline GH concentrations were calculated as the mean of the lowest four samples (5%) in each series.

A one-way ANOVA for repeated measures with Tukey *post hoc* analysis was used to determine differences in body weight, fat mass, fat free mass, leucine Ra, skeletal muscle FSR, S6 and eIF4G phosphorylation, plasma concentrations of insulin, GH, IGF-I, and IGFBP-3, as well as muscle IGF-I mRNA. We performed a log transformation on the skeletal muscle IGF-I data to compensate for the asymmetric distribution of values and the heterogeneous variances. *P* \leq 0.05 was considered statistically significant.

Results

Body weight and fat free mass

The 1-wk LC/HP did not affect fat free mass, which was 50.3 \pm 3.6 kg before and 49.9 \pm 3.6 after the diet. Percent body fat (28.7 \pm 4.7% and 28.3 \pm 4.9%) and total fat mass (20.2 \pm 3.0 kg and 19.7 \pm 3.2 kg) were also not different before *vs.* after the LC/HP. However, the diet slightly, yet significantly, reduced total body weight from 70.5 \pm 3.7 kg to 69.5 \pm 3.6 kg (*P* = 0.01).

Plasma hormone concentrations and muscle IGF-I mRNA

Carbohydrate restriction combined with high protein intake markedly suppressed daily plasma insulin concentration (Fig. 1A). The 24-h insulin concentration (*i.e.* area under the curve) was more than 50% lower (*P* < 0.001) during the second day of the LC/HP (14 \pm 1 μ U/liter \cdot h) *vs.* before the diet (28 \pm 2 μ U/liter \cdot h) and remained suppressed after 1 wk of the diet (12 \pm 1 μ U/liter \cdot h). Not surprisingly, the differences in insulin secretion occurred exclusively after the meals, whereas there was no significant difference in post-absorptive plasma insulin concentration before (7.0 \pm 0.7 μ U/ml) compared with after 2 d (6.3 \pm 1.1 μ U/ml), and 7 d (6.4 \pm 1.0 μ U/ml) of the LC/HP. Mean 24-h GH concentrations, measured in 20-min intervals for 24 h, were unchanged as a result of the LC/HP (Fig. 1B and Table 1). Additionally, no changes in discrete parameters of GH pulsatility (pulse




FIG. 1. A, Plasma insulin concentration for 24 h before the LC/HP and during d 2 and 7 of the diet. B, Plasma GH concentration in 20-min increments for 24 h before the LC/HP and during d 2 and 7 of the diet. Data are presented as mean \pm SE. Area under the curve (AUC) for insulin before the diet was greater than AUC after d 2 and 7 of the diet.

TABLE 1. Parameters of somatotrophic axis before and after 2 and 7 d of the LC/HP

	Before diet	Day 2	Day 7
Mean GH ($\mu\text{g/liter}$)	2.09 ± 0.62	1.82 ± 0.48	1.54 ± 0.33
Pulse frequency (n/24 h)	8.38 ± 0.75	9.25 ± 0.59	9.50 ± 0.78
Pulse amplitude ($\mu\text{g/liter}$)	4.21 ± 1.11	3.75 ± 1.00	3.13 ± 0.76
Basal GH ($\mu\text{g/liter}$)	0.41 ± 0.15	0.56 ± 0.24	0.49 ± 0.15
Total IGF-I ($\mu\text{g/liter}$)	250 ± 43	250 ± 40	233 ± 43
Free IGF-I ($\mu\text{g/liter}$)	1.16 ± 0.19	0.99 ± 0.17	0.79 ± 0.14^a
IGFBP-3 (mg/liter)	3.29 ± 0.48	3.01 ± 0.38	2.82 ± 0.17^a

Data are mean \pm SE.

^a $P < 0.05$, compared with before diet.

frequency, pulse amplitude, baseline GH) were detected during the study (Table 1). Similarly, postabsorptive plasma total IGF-I was not altered during the dietary intervention (Table 1). In contrast, 7 d of carbohydrate restriction combined with high protein intake reduced ($P = 0.002$) free IGF-I and IGFBP-3 concentrations (Table 1), whereas skeletal muscle expression of IGF-I mRNA increased about 2-fold ($P = 0.046$) (Fig. 2).

Whole-body proteolysis and skeletal muscle protein synthesis

Postabsorptive leucine Ra increased approximately 20% ($P = 0.03$) after only 2 d of the LC/HP and remained elevated above basal levels after 1 wk of the diet (Fig. 3). In parallel with the increase in proteolysis, skeletal muscle protein FSR of the vastus lateralis was nearly 2-fold higher ($P < 0.01$) after 7 d of the LC/HP (*i.e.* before, $0.049 \pm 0.004\%/h$; after, $0.094 \pm 0.013\%/h$) (Fig. 4). Despite the marked increase in skeletal muscle FSR in response to the dietary intervention, we found the diet had no effect on total content of either ribosomal protein S6 (2.54 ± 0.51 vs. 2.75 ± 0.43 arbitrary units) or eIF4G (3.71 ± 0.96 vs. 4.92 ± 1.23 arbitrary units). Moreover, the phosphorylation of these proteins was also not affected after 1 wk of the LC/HP (Fig. 5).

Discussion

Maintaining lean tissue mass is essential for the preservation of metabolic and overall health. Preventing a decline in lean tissue mass requires the rate of protein synthesis to be the same or greater than the rate of protein degradation. It has been suggested that adequate dietary carbohydrate and protein are both required for optimal protein balance (7).




FIG. 2. Skeletal muscle IGF-I mRNA expression before and after 7 d of LC/HP. Data are expressed relative to a healthy control subject and normalized to the expression of 18S. *, $P = 0.046$, compared with before the diet.




FIG. 3. Postabsorptive rates of whole-body proteolysis (leucine Ra) before and after 2 and 7 d of the LC/HP. Values are mean \pm SE. *, Significantly different from before the diet.

A LC/HP provides the competing influence of chronic low exposure to insulin, which increases nitrogen excretion (2), and a high protein intake, which induces protein accretion (3). The major finding of the present study was that muscle protein synthesis increased despite strict carbohydrate restriction and a marked reduction in the daily exposure to insulin. This increase in protein synthesis was accompanied by an increase in whole-body proteolysis, whereas fat free mass was unchanged.

High dietary protein content has been found to increase protein synthesis by increasing systemic amino acid availability (18), which is a potent stimulus of muscle protein synthesis (19–22). The present study is the first to demonstrate that a high protein diet can also markedly increase protein synthesis even when dietary carbohydrate intake and 24-h plasma insulin concentration are low. Although insulin has classically been identified as a stimulator of protein synthesis (23), several studies have reported that insulin promotes net muscle protein accretion primarily by inhibiting protein degradation, rather than by stimulating protein synthesis (24–26). Bisschop *et al.* (2) recently reported that 11 d of carbohydrate restriction and a resultant chronic suppression of plasma insulin (without changing dietary protein or




FIG. 4. Postabsorptive rates of skeletal muscle protein FSR before and after 7 d of the LC/HP. *, Significantly different from before the diet.




FIG. 5. Phosphorylation of ribosomal protein S6 (A) and eIF4G (B) in skeletal muscle before and after 7 d of the LC/HP. Data are presented as the amount of phosphorylated (phospho) protein divided by the amount of total protein. Representative blots are displayed for two subjects. Data are mean \pm SE.

caloric content) did not reduce postabsorptive protein synthesis. These data, in combination with the present results, suggest that a low plasma insulin concentration does not impair protein synthesis. Furthermore, our results suggest that dietary protein intake is the primary nutrient-regulating protein synthetic rate.

Although high dietary protein intake (27) and increased systemic amino acid availability (19) stimulate protein synthesis, the mechanism(s) responsible for this increase is not completely clear. The mTOR signaling pathway has been well characterized in the regulation of protein synthesis and is known to be influenced by cellular amino acid concentrations (28). We measured the postabsorptive phosphorylation of two key proteins in the mTOR signaling pathway, ribosomal protein S6 and eIF4G, to determine whether phosphorylation (*i.e.* activation) of these factors mediated the accelerated rate of protein synthesis with our dietary intervention. Interestingly, we found muscle FSR to increase without a change in the phosphorylation of S6 and eIF4G. Similarly, Carroll *et al.* (20) recently reported an enhanced rate of muscle protein synthesis in response to an amino acid infusion without an increase in the phosphorylation of either p70^{S6k} or eukaryotic initiation 4E binding protein. Observations that muscle protein synthesis can be enhanced without increased phosphorylation of these mTOR signaling proteins

indicate that their phosphorylation is not rate limiting for muscle protein synthesis, at least under certain conditions. Protein synthesis can be augmented by other downstream targets of mTOR. Specifically, the binding of eIF4E to eIF4G forms a complex involved in the regulation of translation initiation and is associated with amino acid-induced stimulation of protein synthesis (8, 29). Additionally, our findings of an elevated FSR in the absence of activation of specific mTOR signaling intermediates may reflect an adaptive response to chronic high protein availability combined with a relatively low 24-h exposure to plasma insulin, which may stimulate protein synthesis through an as-yet-undetermined mechanism (30).

The increase in muscle protein synthesis with our LC/HP was accompanied by an increase in protein degradation. Insulin potently inhibits protein degradation (4, 26) and low plasma insulin concentration during fasting (31) or, in type 1 diabetics (32), is associated with an enhanced rate of whole-body proteolysis. Contrary to our findings, Bisschop *et al.* (2) reported no change in postabsorptive leucine Ra after 11 d of a low-carbohydrate diet, despite lower postprandial and postabsorptive insulin concentrations. It remains uncertain why a reduction in plasma insulin concentration did not correspond with an increased postabsorptive rate of proteolysis in their study. In the study by Bisschop *et al.* (2), nitrogen excretion was elevated after the carbohydrate restricted diet, suggesting that overall protein degradation was greater than protein synthesis. One major difference between our study and that of Bisschop *et al.* (2) is that, in their study, they substituted dietary fat for carbohydrate, whereas protein content was not changed. Therefore, data from Bisschop *et al.* (2) suggest that dietary carbohydrate restriction, *per se*, does not affect postabsorptive proteolytic rate. Alternatively, our findings indicate that carbohydrate restriction in combination with a high protein intake can increase the postabsorptive rate of whole-body proteolysis. This is clinically relevant because recommendations for most low-carbohydrate diets suggest an increase in dietary protein content (33). Although it may seem counterintuitive, several studies have reported that increasing dietary protein content enhances the postabsorptive endogenous proteolysis (18, 34, 35). The mechanism(s) by which high protein intake may stimulate proteolytic rate is unknown but may be related to the increased rate of protein synthesis and the possible accretion of tissue protein found with high protein and/or high amino acid availability. Under our dietary conditions, the low 24-h plasma insulin concentration with carbohydrate restriction likely played an important role in increasing protein degradation.

Interestingly, the strict dietary carbohydrate restriction did not alter GH secretion. An energy deficit (*i.e.* fasting or a low-calorie diet) reduces hepatic IGF-I production with a resultant suppression in plasma IGF-I concentration (36). Consequently, because IGF-I is a potent inhibitor of GH secretion, plasma GH concentrations increase markedly in response to the reduction in IGF-I during energy deficit (36). In contrast, our strict carbohydrate restriction without an accompanying energy deficit led to a decrease in free IGF-I without a concomitant rise in plasma GH, suggesting that a different mechanism is responsible for regulating the soma-

trophic axis response to this nutritional manipulation. In addition, muscle IGF-I mRNA expression increased despite stable plasma GH exposure. Previous studies (37) have demonstrated that GH pulsatility may be an independent regulator of muscle IGF-I synthesis, but no change in discrete pulsatile GH parameters was detected in our subjects. Therefore, the increase in muscle IGF-I expression that we found appeared to be independent of plasma GH.

Induction of muscle IGF-I mRNA expression is also not dependent on an increase in plasma IGF-I concentration (38, 39). An alternative explanation for the increased expression of IGF-I in muscle is the increased availability of dietary protein. Muscle IGF-I mRNA has been found to be induced by increasing dietary protein intake (40) and systemic amino acid availability (38). In turn, in the presence of an increased amino acid concentration, local expression of IGF-I is a potent regulator of protein synthesis (39, 41), and amino acid concentration has been found to be highly correlated with muscle FSR (42). These findings suggest that the high intake of dietary protein in the present study and probable rise in systemic amino acid availability may have been responsible for the increased IGF-I mRNA expression, which likely contributed to the elevated skeletal muscle fraction synthetic rate.

Although our LC/HP enhanced both protein synthesis and proteolysis, methodological limitations do not permit a direct quantitative comparison between these two measurements. The marked increase in skeletal muscle FSR, to rates similar to those found after resistance exercise (43, 44) and/or amino acid supplementation (20, 21), compared with the relatively modest increase in whole-body leucine Ra, makes it attractive to suggest that our diet may have induced a net gain in muscle protein. However, this is speculative because we only measured whole-body proteolysis; and therefore, we do not know the rate of protein degradation specific to skeletal muscle. Recent evidence confirms that protein synthesis and proteolysis can differ markedly in different tissues (45), thereby emphasizing the need to be cautious when directly comparing our changes in muscle FSR and whole-body proteolysis. It is also important to consider the timing of the FSR measurement relative to the ingestion of meals. Because we measured skeletal muscle FSR in the postabsorptive state and FSR has been found to increase after meals (1, 18, 27), we cannot rule out the possibility that the average 24-h muscle FSR rate may be even higher than the postabsorptive rates reported here. However, skeletal muscle FSR has been found not to increase after meals when dietary protein ingestion has been high (*i.e.* ≥ 1.5 g/kg·d) for several days before the measurement (18), likely due to the chronic elevation in plasma amino acid concentration with the high protein diet keeping FSR relatively high throughout the day. Therefore, the relatively high rates of postabsorptive muscle FSR observed during our LC/HP are likely not further increased throughout the day. Our finding that fat free mass did not change with our LC/HP helps support the notion that 24-h protein synthesis was not excessively high, relative to proteolysis. However, finding no change in fat free mass in our subjects before *vs.* after our diet was not surprising, given that any increase in lean tissue mass that might have accrued during our 1-wk diet would likely be below the

detection limits of the dual-energy x-ray absorptiometry scanner (46). The effect of longer-term exposure to LC/HP on lean body mass is controversial (47, 48). Although it remains unclear whether our diet increased protein accretion, our data does suggest that increasing dietary protein intake during carbohydrate restriction may prevent the protein loss and the resultant decline of lean tissue mass that has been associated with low carbohydrate diets (2). This finding may have particular relevance for populations characterized by sarcopenia and cachexia.

In conclusion, 1 wk of dietary carbohydrate restriction, in combination with an increase in protein intake, enhanced the rates of skeletal muscle protein synthesis and whole-body proteolysis. These alterations in protein kinetics were associated with a suppressed 24-h insulin exposure and an increase in muscle IGF-I expression but were independent of changes in plasma IGF-I and GH concentrations and activation of ribosomal protein S6 and eIF4G within skeletal muscle. Our results suggest that increasing dietary protein content during a carbohydrate restricted diet may be important for preventing or attenuating a net loss of body protein.

Acknowledgments

We are grateful to Nicolas Knuth for his technical expertise with the GC/MS analysis; Kathy Symons for her assistance with the hormonal assays; and Alla Sakharova, M.D., for help with the pulse analysis. We are also appreciative of the nutrition and nursing staff at the General Clinical Research Center.

Received March 14, 2005. Accepted June 14, 2005.

Address all correspondence and requests for reprints to: Jeffrey Horowitz, University of Michigan, Division of Kinesiology, 401 Washtenaw Avenue, Ann Arbor, Michigan 48109-2208. E-mail: jeffhoro@umich.edu.

This work was supported by National Institutes of Health Grant MO1RR042 (to J.F.H.) and by a Veterans Affairs Medical Research Service Merit Review (to A.L.B.).

References

1. Darmaun D 1999 Role of nutrients in the regulation of *in vivo* protein metabolism in humans. *Acta Paediatr Suppl* 88:92–94
2. Bisschop PH, De Sain-Van Der Velden MG, Stellaard F, Kuipers F, Meijer AJ, Sauerwein HP, Romijn JA 2003 Dietary carbohydrate deprivation increases 24-hour nitrogen excretion without affecting postabsorptive hepatic or whole body protein metabolism in healthy men. *J Clin Endocrinol Metab* 88:3801–3805
3. Oddoye EA, Margen S 1979 Nitrogen balance studies in humans: long-term effect of high nitrogen intake on nitrogen accretion. *J Nutr* 109:363–377
4. Fukagawa NK, Minaker KL, Rowe JW, Goodman MN, Matthews DE, Bier DM, Young VR 1985 Insulin-mediated reduction of whole body protein breakdown. Dose-response effects on leucine metabolism in postabsorptive men. *J Clin Invest* 76:2306–2311
5. Balage M, Sinaud S, Prod'homme M, Dardevet D, Vary TC, Kimball SR, Jefferson LS, Grizard J 2001 Amino acids and insulin are both required to regulate assembly of the eIF4E. eIF4G complex in rat skeletal muscle. *Am J Physiol Endocrinol Metab* 281:E565–E574
6. Kimball SR, Farrell PA, Jefferson LS 2002 Invited review: role of insulin in translational control of protein synthesis in skeletal muscle by amino acids or exercise. *J Appl Physiol* 93:1168–1180
7. Wolfe RR 2002 Regulation of muscle protein by amino acids. *J Nutr* 132:3219S–S3224S
8. Anthony JC, Anthony TG, Kimball SR, Vary TC, Jefferson LS 2000 Orally administered leucine stimulates protein synthesis in skeletal muscle of postabsorptive rats in association with increased eIF4F formation. *J Nutr* 130:139–145
9. Anthony JC, Reiter AK, Anthony TG, Crozier SJ, Lang CH, MacLean DA, Kimball SR, Jefferson LS 2002 Orally administered leucine enhances protein synthesis in skeletal muscle of diabetic rats in the absence of increases in 4E-BP1 or S6K1 phosphorylation. *Diabetes* 51:928–936
10. Black AE, Coward WA, Cole TJ, Prentice AM 1996 Human energy expen-

- diture in affluent societies: an analysis of 574 doubly-labelled water measurements. *Eur J Clin Nutr* 50:72–92
11. **Bialostosky K, Wright JD, Kennedy-Stephenson J, McDowell M, Johnson CL** 2002 Dietary intake of macronutrients, micronutrients, and other dietary constituents: United States 1988–94. *Vital Health Stat* 11:1–158
 12. **Jensen MD, Heiling VJ** 1991 Heated hand vein blood is satisfactory for measurements during free fatty acid kinetic studies. *Metabolism* 40:406–409
 13. **Patterson BW, Zhang XJ, Chen Y, Klein S, Wolfe RR** 1997 Measurement of very low stable isotope enrichments by gas chromatography/mass spectrometry: application to measurement of muscle protein synthesis. *Metabolism* 46:943–948
 14. **Wolfe RR, Goodenough RD, Wolfe MH, Royle GT, Nadel ER** 1982 Isotopic analysis of leucine and urea metabolism in exercising humans. *J Appl Physiol* 52:458–466
 15. **Ririe KM, Rasmussen RP, Wittwer CT** 1997 Product differentiation by analysis of DNA melting curves during the polymerase chain reaction. *Anal Biochem* 245:154–160
 16. **Schmittgen TD, Zakrajsek BA, Mills AG, Gorn V, Singer MJ, Reed MW** 2000 Quantitative reverse transcription-polymerase chain reaction to study mRNA decay: comparison of endpoint and real-time methods. *Anal Biochem* 285:194–204
 17. **Steele R** 1959 Influences of glucose loading and of injected insulin on hepatic glucose output. *Ann NY Acad Sci* 82:420–430
 18. **Motil KJ, Matthews DE, Bier DM, Burke JF, Munro HN, Young VR** 1981 Whole-body leucine and lysine metabolism: response to dietary protein intake in young men. *Am J Physiol* 240:E712–E721
 19. **Bohe J, Low A, Wolfe RR, Rennie MJ** 2003 Human muscle protein synthesis is modulated by extracellular, not intramuscular amino acid availability: a dose-response study. *J Physiol* 552:315–324
 20. **Carroll CC, Fluckey JD, Williams RH, Sullivan DH, Trappe TA** 2005 Human soleus and vastus lateralis muscle protein metabolism with an amino acid infusion. *Am J Physiol Endocrinol Metab* 288:E479–E485
 21. **Paddon-Jones D, Sheffield-Moore M, Zhang XJ, Volpi E, Wolf SE, Aarsland A, Ferrando AA, Wolfe RR** 2004 Amino acid ingestion improves muscle protein synthesis in the young and elderly. *Am J Physiol Endocrinol Metab* 286:E321–E328
 22. **Volpi E, Ferrando AA, Yeckel CW, Tipton KD, Wolfe RR** 1998 Exogenous amino acids stimulate net muscle protein synthesis in the elderly. *J Clin Invest* 101:2000–2007
 23. **Biolo G, Declan Fleming RY, Wolfe RR** 1995 Physiologic hyperinsulinemia stimulates protein synthesis and enhances transport of selected amino acids in human skeletal muscle. *J Clin Invest* 95:811–819
 24. **Fryburg DA, Jahn LA, Hill SA, Oliveras DM, Barrett EJ** 1995 Insulin and insulin-like growth factor-I enhance human skeletal muscle protein anabolism during hyperaminoacidemia by different mechanisms. *J Clin Invest* 96:1722–1729
 25. **Gelfand RA, Barrett EJ** 1987 Effect of physiologic hyperinsulinemia on skeletal muscle protein synthesis and breakdown in man. *J Clin Invest* 80:1–6
 26. **Meek SE, Persson M, Ford GC, Nair KS** 1998 Differential regulation of amino acid exchange and protein dynamics across splanchnic and skeletal muscle beds by insulin in healthy human subjects. *Diabetes* 47:1824–1835
 27. **Garlick PJ, McNurlan MA, Ballmer PE** 1991 Influence of dietary protein intake on whole-body protein turnover in humans. *Diabetes Care* 14:1189–1198
 28. **Beugnet A, Tee AR, Taylor PM, Proud CG** 2003 Regulation of targets of mTOR (mammalian target of rapamycin) signalling by intracellular amino acid availability. *Biochem J* 372:555–566
 29. **Vary TC, Jefferson LS, Kimball SR** 1999 Amino acid-induced stimulation of translation initiation in rat skeletal muscle. *Am J Physiol* 277:E1077–E1086
 30. **Fluckey JD, Dupont-Versteegden EE, Knox M, Gaddy D, Tesch PA, Peterson CA** 2004 Insulin facilitation of muscle protein synthesis following resistance exercise in hindlimb-suspended rats is independent of a rapamycin-sensitive pathway. *Am J Physiol Endocrinol Metab* 287:E1070–E1075
 31. **Carlson MG, Snead WL, Campbell PJ** 1994 Fuel and energy metabolism in fasting humans. *Am J Clin Nutr* 60:29–36
 32. **Nair KS, Ford GC, Ekberg K, Fernqvist-Forbes E, Wahren J** 1995 Protein dynamics in whole body and in splanchnic and leg tissues in type I diabetic patients. *J Clin Invest* 95:2926–2937
 33. **Freedman MR, King J, Kennedy E** 2001 Popular diets: a scientific review. *Obes Res* 9(Suppl 1):1S–40S
 34. **Manary MJ, Yarasheski KE, Smith S, Abrams ET, Hart CA** 2004 Protein quantity, not protein quality, accelerates whole-body leucine kinetics and the acute-phase response during acute infection in marasmic Malawian children. *Br J Nutr* 92:589–595
 35. **Tawa Jr NE, Goldberg AL** 1992 Suppression of muscle protein turnover and amino acid degradation by dietary protein deficiency. *Am J Physiol* 263:E317–E325
 36. **Ho PJ, Friberg RD, Barkan AL** 1992 Regulation of pulsatile growth hormone secretion by fasting in normal subjects and patients with acromegaly. *J Clin Endocrinol Metab* 75:812–819
 37. **Isgaard J, Carlsson L, Isaksson OG, Jansson JO** 1988 Pulsatile intravenous growth hormone (GH) infusion to hypophysectomized rats increases insulin-like growth factor I messenger ribonucleic acid in skeletal tissues more effectively than continuous GH infusion. *Endocrinology* 123:2605–2610
 38. **Moloney AP, Beermann DH, Gerrard D, Robinson TF, Finnerty KD** 1998 Temporal change in skeletal muscle IGF-I mRNA abundance and nitrogen metabolism responses to abomasal casein infusion in steers. *J Anim Sci* 76:1380–1388
 39. **Svanberg E, Zachrisson H, Ohlsson C, Iresjo BM, Lundholm KG** 1996 Role of insulin and IGF-I in activation of muscle protein synthesis after oral feeding. *Am J Physiol* 270:E614–E620
 40. **Brameld JM, Atkinson JL, Saunders JC, Pell JM, Buttery PJ, Gilmour RS** 1996 Effects of growth hormone administration and dietary protein intake on insulin-like growth factor I and growth hormone receptor mRNA expression in porcine liver, skeletal muscle, and adipose tissue. *J Anim Sci* 74:1832–1841
 41. **Svanberg E, Moller-Loswick AC, Matthews DE, Korner U, Andersson M, Lundholm K** 1996 Effects of amino acids on synthesis and degradation of skeletal muscle proteins in humans. *Am J Physiol* 271:E718–E724
 42. **Lang CH, Frost RA, Kumar V, Wu D, Vary TC** 2000 Impaired protein synthesis induced by acute alcohol intoxication is associated with changes in eIF4E in muscle and eIF2B in liver. *Alcohol Clin Exp Res* 24:322–331
 43. **Phillips SM, Tipton KD, Aarsland A, Wolf SE, Wolfe RR** 1997 Mixed muscle protein synthesis and breakdown after resistance exercise in humans. *Am J Physiol* 273:E99–E107
 44. **Trappe TA, Raue U, Tesch PA** 2004 Human soleus muscle protein synthesis following resistance exercise. *Acta Physiol Scand* 182:189–196
 45. **Sheffield-Moore M, Paddon-Jones D, Sanford AP, Rosenblatt JI, Matlock AG, Cree MG, Wolfe RR** 2005 Mixed muscle and hepatic derived plasma protein metabolism is differentially regulated in older and younger men following resistance exercise. *Am J Physiol Endocrinol Metab* 288:E922–E929
 46. **Humphries IR, Hua V, Ban L, Gaskin KJ, Howman-Giles R** 2000 Validation of estimates of body composition by dual-energy x-ray absorptiometry in fluid overload conditions. *Ann NY Acad Sci* 904:101–103
 47. **Meckling KA, O'Sullivan C, Saari D** 2004 Comparison of a low-fat diet to a low-carbohydrate diet on weight loss, body composition, and risk factors for diabetes and cardiovascular disease in free-living, overweight men and women. *J Clin Endocrinol Metab* 89:2717–2723
 48. **Volek JS, Sharman MJ, Love DM, Avery NG, Gomez AL, Scheett TP, Kraemer WJ** 2002 Body composition and hormonal responses to a carbohydrate-restricted diet. *Metabolism* 51:864–870

JCEM is published monthly by The Endocrine Society (<http://www.endo-society.org>), the foremost professional society serving the endocrine community.